Published in J Clin Oncol on October 08, 2012
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol (2014) 1.04
Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000. PLoS One (2015) 1.01
CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi. PLoS One (2016) 0.87
Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev (2013) 0.86
Patients with AIDS-defining cancers are not universally screened for HIV: a 10-year retrospective analysis of HIV-testing practices in a Swiss university hospital. HIV Med (2014) 0.83
How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. Blood (2014) 0.83
Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma (2016) 0.80
Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis (2014) 0.80
HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape. Pathog Dis (2015) 0.79
Management of HIV-associated Hodgkin lymphoma: how far we have come. J Clin Oncol (2012) 0.77
The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care. Oncologist (2014) 0.77
Spontaneous Regression of Refractory Diffuse Large B-Cell Lymphoma with Improvement in Immune Status with ART in a Patient with HIV: A Case Report and Literature Review. Am J Case Rep (2015) 0.75
Infectious and Non-infectious Etiologies of Cardiovascular Disease in Human Immunodeficiency Virus Infection. Open AIDS J (2016) 0.75
Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer. Surg Oncol Clin N Am (2017) 0.75
The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma. Br J Cancer (2015) 0.75
A declining CD4 count and diagnosis of HIV-associated Hodgkin lymphoma: do prior clinical symptoms and laboratory abnormalities aid diagnosis? PLoS One (2014) 0.75
Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphoma. Bone Marrow Transplant (2016) 0.75
HIV-associated hematologic malignancies: Experience from a Tertiary Cancer Center in India. Indian J Med Paediatr Oncol (2016) 0.75
The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2017) 0.75
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med (1998) 8.24
Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer (2008) 6.13
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol (2003) 4.15
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst (2000) 3.47
AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst (2007) 3.28
Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer (2004) 2.98
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood (2006) 2.90
Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis (2004) 2.42
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood (2006) 2.09
Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer (2010) 1.75
Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol (1987) 1.57
High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer (2008) 1.30
Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood (2004) 1.26
British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med (2008) 1.23
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica (2007) 1.10
Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS (2010) 1.05
Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood (2002) 1.02
The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica (2005) 1.02
HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood (2011) 1.02
BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol (2003) 0.97
Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol (2006) 0.91
Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. Leuk Lymphoma (2009) 0.81
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med (2005) 5.54
Evolving general practice consultation in Britain: issues of length and context. BMJ (2002) 5.15
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med (2002) 4.89
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 3.89
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood (2008) 3.19
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol (2005) 3.05
Microseizures and the spatiotemporal scales of human partial epilepsy. Brain (2010) 2.81
Changes in alcohol consumption in pregnant Australian women between 2007 and 2011. Med J Aust (2013) 2.76
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
A comparison of research general practices and their patients with other practices--a cross-sectional survey in Trent. Br J Gen Pract (2002) 2.68
Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. BMJ (2012) 2.66
Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment. Nature (2002) 2.64
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr (2010) 2.59
Control of bovine TB in cattle and wildlife. Vet Rec (2011) 2.50
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol (2008) 2.38
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood (2012) 2.37
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
A systematic review finds prediction models for chronic kidney disease were poorly reported and often developed using inappropriate methods. J Clin Epidemiol (2012) 2.33
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol (2011) 2.26
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Predicting complications from acute cough in pre-school children in primary care: a prospective cohort study. Br J Gen Pract (2004) 2.23
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest (2005) 2.15
Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol (2013) 2.09
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol (2013) 2.06
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood (2004) 2.01
Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol (2005) 1.99
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol (2002) 1.98
Hematopoiesis is not clonal in healthy elderly women. Blood (2008) 1.95
The duration of acute cough in pre-school children presenting to primary care: a prospective cohort study. Fam Pract (2003) 1.93
FLT3 mutations in childhood acute lymphoblastic leukemia. Blood (2003) 1.91
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood (2008) 1.90
Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2008) 1.85
The strength of primary care in Europe: an international comparative study. Br J Gen Pract (2013) 1.85
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis (2006) 1.78
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2012) 1.76
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood (2008) 1.72
Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS (2007) 1.72
Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS (2013) 1.71
A prospective cohort study of geriatric syndromes among older medical patients admitted to acute care hospitals. J Am Geriatr Soc (2011) 1.70
Current calibration, treatment, and treatment planning techniques among institutions participating in the Children's Oncology Group. Int J Radiat Oncol Biol Phys (2003) 1.70
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol (2006) 1.68
Significant differences in the analytic concordance between anti-dsDNA IgG antibody assays for the diagnosis of systemic lupus erythematosus--implications for inter-laboratory testing. Clin Chim Acta (2011) 1.66
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res (2009) 1.65
Fifty years of multicentric Castleman's disease. Acta Oncol (2004) 1.65
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol (2013) 1.63
Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol (2007) 1.62
The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood (2013) 1.62
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A (2009) 1.61
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood (2013) 1.61
New challenges to medicare beneficiary access to mAbs. MAbs (2010) 1.60
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer (2008) 1.60
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS (2003) 1.60
External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol (2014) 1.57
SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood (2011) 1.57
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med (2007) 1.54
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood (2007) 1.53
Primary esophageal carcinoma in the era of highly active antiretroviral therapy. Arch Intern Med (2010) 1.52
Initial experience with teriparatide in the United States. Curr Med Res Opin (2006) 1.51
Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr (2005) 1.50
Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect (2010) 1.49
Achieving compliance with the European Working Time Directive in a large teaching hospital: a strategic approach. Clin Med (2004) 1.49
KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev (2010) 1.48
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood (2011) 1.46